Aduro Biotech Appoints Aimee Luck Murphy as Vice President of Clinical Development and Operations

BERKELEY, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that Aimee Luck Murphy has been promoted to the position of vice president of clinical development and operations.

“Aimee’s promotion speaks to her invaluable contributions to Aduro and our clinical programs,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Her achievements, which include overseeing our Phase 2 clinical trials in pancreatic cancer and the development of CRS-207 in mesothelioma, play a key role in the advancement of our clinical programs. She has been an instrumental member of our team and we look forward to her continued leadership.”

Ms. Murphy began consulting for Aduro on the LADD program in 2009.  She joined Aduro as director of clinical operations in 2011 and was promoted to senior director of clinical development and operations in 2013.  Prior to Aduro, Ms. Murphy advanced the development of the LADD platform at both Cerus Corporation and Anza Therapeutics, where she managed the first Phase 1 studies to support what are now Aduro’s LADD clinical programs. Prior to working on LADD, she developed prophylactic vaccines and drugs for oncology and infectious diseases at VaxGen, Coulter Pharmaceuticals, and Shaman Pharmaceuticals. Additionally, Ms. Murphy brings experience in quality assurance from Bayer Pharmaceuticals. She holds a BS in Biology from Pepperdine University.

About Aduro

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s technology platforms, which are designed to harness the body’s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro’s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro’s cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, our technology platforms and development programs. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “potential,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our dependence on our lead product candidate, CRS-207, and GVAX Pancreas, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading “Risk Factors” contained in the most recent Form 10-Q which is on file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CONTACT: Contact:		
Sylvia Wheeler	
SVP, Corporate Affairs
510 809 9264		

Media Contact:
Angela Bitting
925 202 6211

Mike Beyer
Sam Brown, Inc.
312 961 2502